Immunomic Therapeutics’ VP, Clinical Development to Participate at Precision Medicine’s Webinar on Oncolytic Therapeutic Development
ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will be participating in Precision Medicine’s webinar on utilizing liquid biopsy to promote oncolytic therapeutic development. On Thursday, September 24, Vice President of Clinical Development at Immunomic, Dr. Andrew Eisen, will be discussing methods and tools to utilize liquid biopsy to promote oncology therapeutic development alongside Akoya Biosciences’ CMO, Dr. Gerald Messerschmidt and Sr. Vice President, Dr. Darren Davis.
This webinar will examine:
- Clinical utility of liquid biopsy and specifically of circulating tumor cells (CTC) biomarkers
- Methods to capture and concentrate CTCs to enable effective analysis
- Tools to image CTCs and analyze CTC biomarkers
- Case study exploring CTCs as a tool to understand drug pharmacodynamics in melanoma patients
Webinar details are as follows:
Title: Utilizing Liquid Biopsy to Promote Oncolytic Therapeutic Development
Date and Time: Thursday, September 24, 2020 12:00 PM ET
Register here: http://ow.ly/KUAv50BlZDf
ITI’s investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein 1, an endogenous protein in humans, for immune processing. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach puts UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. UNITE is currently being employed in a Phase II clinical trial as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP1 nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body’s natural biochemistry to develop vaccines that generate broad immune responses. ITI’s UNITE platform could potentially have broad therapeutic applications in oncology, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics and ITI has built a large pipeline from UNITE with six oncology programs and two allergy programs. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com.
Source: Immunomic Therapeutics, Inc.